- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function11/5/07 9:30 am ESTORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin calcium) Tablets 80 mg had stabilization or improvement in kidney function. These results were demonstrated in patients with or without chronic kidney disease, metabolic syndrome or type 2 diabetes. This post-hoc analysis of the landmark Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study,more...
New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to Be Presented at Upcoming Annual Scientific Sessions of the American Heart Association11/4/07 8:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the cardiovascular and kidney function effects of Lipitor® (atorvastatin calcium) Tablets will be presented next week at the Annual Scientific Sessions of the American Heart Association. SPARCL Trial A new post-hoc analysis (planned after the study completed) of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study lookedmore...
10/30/07 3:00 am EDTTOKYO & NEW YORK--(BUSINESS WIRE)--Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] (hereinafter, Taisho) and Pfizer Inc. [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) have concluded a letter of intent with regard to TS-032, a new schizophrenia drug candidate discovered by Taisho and currently in the pre-clinical stage. The letter of intent relates to amore...
Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial Impact10/29/07 3:17 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010. The decision — which resulted from a patent challenge by generic manufacturers Ranbaxy Laboratories Limited and Basics GmbH — has no immediate commercialmore...
10/25/07 4:45 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer said today that after a 31-year career Vice Chairman David L. Shedlarz will retire from the company at the end of this year. Mr. Shedlarz’s contributions to the company include helping to shape the strategic direction that drove Pfizer’s growth to pharmaceutical industry leadership; fifteen years of service on Pfizer’s senior management committee and ten as its Chief Financial Officer; andmore...
10/25/07 1:00 pm EDTNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent fourth-quarter, 2007, dividend on the company's common stock, payable December 4, 2007, to shareholders of record at the close of business on November 9, 2007. Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The fourth-quartermore...
10/23/07 9:51 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The calcium salt patent expires in July 2010. The patent was challenged by generic manufacturer Lek Pharmaceuticals D.D., and is one of four separate challenges to the calcium salt patent by genericmore...
Pfizer Reports Third-Quarter 2007 Results; Reconfirms 2007 and 2008 Revenue and Adjusted Diluted EPS(1) Guidance10/18/07 6:30 am EDT
- Third-Quarter 2007 Reported Diluted EPS of $0.11 Represents a Decline of 76% Compared to the Same Period Last Year and Includes Charges of $0.31 ($2.8 Billion Pre-Tax) Related to a Decision to Exit Exubera
- Adjusted Diluted EPS(1) of $0.58 for the Third-Quarter 2007 Represents an Increase of 7% Compared to the Same Period a Year Ago
- New Products(3) Posted Significant Growth in Revenues; Overall Third-Quarter 2007 Revenues were Adversely Impacted by Loss of U.S. Exclusivity for Norvasc and Zoloft
- Worldwide Lipitor Revenues were $3.2 Billion in the Third Quarter of 2007 Compared to $3.3 Billion in the Third Quarter of 2006
10/15/07 12:01 am EDT
Company Aims To Open Information Exchange with Doctors through Unique Online CollaborationNEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc (www.pfizer.com) and Sermo (www.sermo.com), the nation’s largest online physician community, today announced a strategic collaboration designed to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care. Sermo is a Web-based community where physicians share observations from daily practice, discuss emerging trends and provide newmore...
Research Reveals New Trends and Best Practices among Multinational Corporations Engaging in International Corporate Volunteering Programs10/11/07 11:00 am EDT
Brookings Institution, Pfizer and FSG Social Impact Advisors Release Findings from Independent Analysis of International Corporate Volunteering ProgramsWASHINGTON--(BUSINESS WIRE)--The Brookings Institution’s Initiative on International Volunteering and Service, FSG Social Impact Advisors and Pfizer Inc, today released a landmark independent report researched and written by FSG on the state of international corporate volunteering (ICV) programs. The report details the landscape of this emerging trend among multinationals, the perceived business value of ICV and community impact, and the businessmore...